Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Selgantolimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 known ✓ | Q9NR97 | 15/20 | 1.00 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Selgantolimod SCHEMBL29368858 | 1.00 | TLR8 (1.00) | TLR8TLR7KCNH2NLRP3 | |
| Selgantolimod SCHEMBL18109408 | 1.00 | TLR8 (1.00) | TLR8TLR7KCNH2NLRP3 | |
| Selgantolimod SCHEMBL31141439 | 1.00 | TLR8 (1.00) | TLR8TLR7KCNH2NLRP3 | |
| Selgantolimod SCHEMBL18109405 | 1.00 | TLR8 (1.00) | TLR8TLR7KCNH2NLRP3 | |
| Selgantolimod SCHEMBL22613603 | 0.99 | TLR8 (0.98) | TLR8TLR7KCNH2NLRP3 | |
| Selgantolimod SCHEMBL22558375 | 0.99 | TLR8 (0.98) | TLR8TLR7KCNH2NLRP3 | |
| Selgantolimod SCHEMBL22558518 | 0.99 | TLR8 (0.98) | TLR8TLR7KCNH2NLRP3 | |
| Selgantolimod SCHEMBL28692784 | 0.99 | TLR8 (0.98) | TLR8TLR7KCNH2NLRP3 | |
| SCHEMBL18109386 | 0.97 | TLR8 (0.94) | TLR8TLR7KCNH2NLRP3 | |
| SCHEMBL18109383 | 0.97 | TLR8 (0.94) | TLR8TLR7KCNH2NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377100-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20220305115-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-09-29 | — | — | US | disclosed |
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-14 | — | — | US | disclosed |
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-14 | — | — | US | disclosed |
| EP-3956328-A1 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | GILEAD SCIENCES, INC. (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3956328-A1 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | GILEAD SCIENCES, INC. (US) | 2022-02-23 | — | — | EP | disclosed |
| WO-2020255038-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020214663-A1 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | GILEAD SCIENCES, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020214663-A1 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | GILEAD SCIENCES, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| EP-3722297-A1 | TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS | Gilead Sciences, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| US-9670205-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670205-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670205-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| WO-2017048727-A1 | MODULATORS OF TOLL-LIKE RECPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20170071944-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170071944-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
| EP-3097102-A1 | TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS | Gilead Sciences, Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | TLR8 1/4885TLR7 9/4885KCNH2 4348/4885 |
| US-12377100-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | TLR8 1/4885TLR7 9/4885KCNH2 4348/4885 |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | TLR8 1/4885TLR7 9/4885KCNH2 4348/4885 |
| US-20220305115-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | HAVCR2, ENTPD5, HMGB3 | TLR8 158/4885TLR7 60/4885KCNH2 4025/4885 |
| US-20170071944-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR8, TLR3, TLR6 | TLR8 1/4885TLR7 4/4885KCNH2 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.